Additional C36 analogues are also being synthesized to improve the binding affinity of the drug to LMTK3 and to increase its inhibitory properties against LMTK3 activity both in vitro (kinetic analysis) and in breast cancer cell lines. The gene discussed is LMTK3; the disease is breast carcinoma.